ECSP19031458A - PIRIDO [3,4-b] SUBSTITUTE INDOLES FOR TREATMENT OF DISORDERS OF CARTILAGE - Google Patents

PIRIDO [3,4-b] SUBSTITUTE INDOLES FOR TREATMENT OF DISORDERS OF CARTILAGE

Info

Publication number
ECSP19031458A
ECSP19031458A ECSENADI201931458A ECDI201931458A ECSP19031458A EC SP19031458 A ECSP19031458 A EC SP19031458A EC SENADI201931458 A ECSENADI201931458 A EC SENADI201931458A EC DI201931458 A ECDI201931458 A EC DI201931458A EC SP19031458 A ECSP19031458 A EC SP19031458A
Authority
EC
Ecuador
Prior art keywords
cartilage
indoles
treatment
disorders
pirido
Prior art date
Application number
ECSENADI201931458A
Other languages
Spanish (es)
Inventor
Volkmar Wehner
Dirk Gretzke
Olaf Ritzeler
Friedemann Schmidt
Uwe Heinelt
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP19031458A publication Critical patent/ECSP19031458A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a 9H pirido[3,4-b]indoles sustituidos con 8-arilo y sustituidos con 8-heteroarilo de fórmula I, en la que A, E, G, R1 a R6 y R10 son como se definen en las reivindicaciones, que estimulan la condrogénesis y la síntesis de la matriz del cartílago y se pueden usar en el tratamiento de trastornos y afecciones del cartílago en los que se desea la regeneración del cartílago dañado, por ejemplo, enfermedades de las articulaciones tales como la osteoartritis. La invención se refiere además a procedimientos para la síntesis de los compuestos de fórmula I, su uso como productos farmacéuticos, y a composiciones farmacéuticas que los comprenden.The present invention relates to 8-aryl substituted and 8-heteroaryl substituted 9H-pyrido [3,4-b] indoles of formula I, wherein A, E, G, R1 to R6 and R10 are as defined in claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis . The invention further relates to processes for the synthesis of the compounds of formula I, their use as pharmaceuticals, and to pharmaceutical compositions comprising them.

ECSENADI201931458A 2016-11-07 2019-05-06 PIRIDO [3,4-b] SUBSTITUTE INDOLES FOR TREATMENT OF DISORDERS OF CARTILAGE ECSP19031458A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306452.0A EP3318563A1 (en) 2016-11-07 2016-11-07 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Publications (1)

Publication Number Publication Date
ECSP19031458A true ECSP19031458A (en) 2019-05-31

Family

ID=57286428

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201931458A ECSP19031458A (en) 2016-11-07 2019-05-06 PIRIDO [3,4-b] SUBSTITUTE INDOLES FOR TREATMENT OF DISORDERS OF CARTILAGE

Country Status (35)

Country Link
US (2) US11130755B2 (en)
EP (3) EP3318563A1 (en)
JP (1) JP7046063B2 (en)
KR (1) KR102490199B1 (en)
CN (1) CN110382496B (en)
AR (1) AR110136A1 (en)
AU (2) AU2017353381B2 (en)
BR (1) BR112019007901A2 (en)
CA (1) CA3042332A1 (en)
CL (1) CL2019001251A1 (en)
CO (1) CO2019005090A2 (en)
CR (1) CR20190217A (en)
DK (1) DK3535263T3 (en)
DO (1) DOP2019000112A (en)
EA (1) EA038365B1 (en)
EC (1) ECSP19031458A (en)
ES (1) ES2837765T3 (en)
HR (1) HRP20201754T1 (en)
HU (1) HUE052187T2 (en)
IL (1) IL265982B (en)
LT (1) LT3535263T (en)
MA (1) MA45803B1 (en)
MX (1) MX2019005308A (en)
MY (1) MY189589A (en)
PE (1) PE20191032A1 (en)
PH (1) PH12019500997A1 (en)
PT (1) PT3535263T (en)
RS (1) RS61172B1 (en)
SG (1) SG11201903195YA (en)
SI (1) SI3535263T1 (en)
TN (1) TN2019000143A1 (en)
TW (1) TWI753966B (en)
UY (1) UY37473A (en)
WO (1) WO2018083157A1 (en)
ZA (1) ZA201902111B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
AU2018368790A1 (en) 2017-11-20 2020-06-25 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2021510153A (en) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ Methods, Therapeutic Methods, and Compositions to Increase Pancreatic Beta Cell Proliferation
WO2019183245A1 (en) * 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
MX2022001516A (en) * 2019-08-06 2022-03-11 Domain Therapeutics 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists.
CN114763347A (en) * 2021-01-15 2022-07-19 华东师范大学 Compound for inducing mesenchymal stem cells to differentiate towards cartilage and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
ECSP951529A (en) 1995-09-05 1997-05-16 PHARMACEUTICAL COMPOUNDS
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
AU2002352498A1 (en) 2001-11-07 2003-05-19 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
FR2838123B1 (en) * 2002-04-04 2005-06-10 Sanofi Synthelabo NOVEL SUBSTITUTED INDOLOZIN-1,2,3 DERIVATIVES, SELECTIVE B-FGF INHIBITORS
WO2006013739A1 (en) * 2004-08-04 2006-02-09 Konica Minolta Holdings, Inc. Organic electroluminescent device, illuminating device and display
AR062522A1 (en) 2006-08-25 2008-11-12 Ares Trading Sa TREATMENT OF DISORDERS IN CARTILAGOS
WO2008132454A1 (en) 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
WO2010038153A1 (en) 2008-10-01 2010-04-08 The University Of British Columbia Use of sox transcription factor acti\ators for stimulating chondrogenesis
EP2455378A1 (en) * 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
JP5854492B2 (en) 2011-02-24 2016-02-09 国立大学法人 岡山大学 Chondrocyte differentiation inducer
UY35809A (en) 2013-11-05 2015-05-29 Bayer Pharma AG (AZA) PIRIDOPIRAZOLOPIRIMIDINONAS AND INDAZOLOPIRIMIDINONAS AND ITS USES
JP2015107945A (en) 2013-12-05 2015-06-11 国立大学法人京都大学 Compound and pharmaceutical composition relating to neurogenesis
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Also Published As

Publication number Publication date
HRP20201754T1 (en) 2020-12-25
AU2017353381A1 (en) 2019-05-30
US11827633B2 (en) 2023-11-28
US11130755B2 (en) 2021-09-28
SG11201903195YA (en) 2019-05-30
US20220041596A1 (en) 2022-02-10
PT3535263T (en) 2020-12-18
EP3535263A1 (en) 2019-09-11
AR110136A1 (en) 2019-02-27
CN110382496A (en) 2019-10-25
AU2017353381B2 (en) 2021-05-27
SI3535263T1 (en) 2020-11-30
EA201991144A1 (en) 2019-10-31
LT3535263T (en) 2020-12-28
TW201831475A (en) 2018-09-01
KR20190072654A (en) 2019-06-25
MY189589A (en) 2022-02-18
DOP2019000112A (en) 2019-07-31
MA45803A1 (en) 2020-05-29
CR20190217A (en) 2019-08-06
IL265982B (en) 2021-05-31
EP3792262A1 (en) 2021-03-17
TWI753966B (en) 2022-02-01
CO2019005090A2 (en) 2019-07-31
HUE052187T2 (en) 2021-04-28
ES2837765T3 (en) 2021-07-01
ZA201902111B (en) 2020-10-28
EA038365B1 (en) 2021-08-16
EP3535263B1 (en) 2020-09-30
AU2021221468A1 (en) 2021-09-16
BR112019007901A2 (en) 2019-07-02
CN110382496B (en) 2022-08-09
AU2021221468B2 (en) 2023-10-26
MA45803B1 (en) 2020-10-28
EP3318563A1 (en) 2018-05-09
DK3535263T3 (en) 2020-12-21
PH12019500997A1 (en) 2019-08-05
KR102490199B1 (en) 2023-01-20
JP7046063B2 (en) 2022-04-01
TN2019000143A1 (en) 2020-10-05
RS61172B1 (en) 2021-01-29
WO2018083157A1 (en) 2018-05-11
PE20191032A1 (en) 2019-08-05
CL2019001251A1 (en) 2019-10-04
CA3042332A1 (en) 2018-05-11
UY37473A (en) 2018-06-29
JP2019537587A (en) 2019-12-26
IL265982A (en) 2019-06-30
MX2019005308A (en) 2019-08-05
US20200095242A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
ECSP19031458A (en) PIRIDO [3,4-b] SUBSTITUTE INDOLES FOR TREATMENT OF DISORDERS OF CARTILAGE
CL2019001626A1 (en) Small molecule inhibitors of the jak family of kinases.
DOP2018000204A (en) NICOTINIC ACETILCOLINE RECEPTORS ALOSTERIC MODULATORS
CL2012001073A1 (en) Compounds derived from pyrido [4,3-d] pyrimidin-5-one, their pharmaceutical compositions and their use as kinase inhibitors to treat asthma, COPD, ulcerative colitis, bronchitis, lupus, breast cancer, Alzheimer's disease, Alzheimer's disease parkinson's, osteoporosis, multiple sclerosis, diabetes, eye disorders, restenosis, inflammatory diseases.
UY34917A (en) INHIBITORS OF THE PRODUCTION OF LEUCOTRIENO-A4-HIDROLASA (LTA4H), PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESS FOR THEIR PREPARATION
CO6670575A2 (en) Substituted aminopyrazoloqinazolines, useful in the treatment of proliferative diseases and pharmaceutical compositions that continue them
SV2017005434A (en) 2-AMINO-3,5-DIFLUORO-6-METHYL-6-PHENYL-3,4,5,6-TETRAHYDROPIRIDINS IN QUALITY OF BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PA8814301A1 (en) COMPOUNDS AND COMPOSITIONS AS CINASE INHIBITORS
CR20130371A (en) IMIDAZO [5,1-f] [1,2,4] TRIAZINS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
UY36226A (en) HETEROCYCLIC CARBOXYLIC ACIDS AS SOLUBLE CYCLING GUANILATE ACTIVATORS
GT201600091A (en) DERIVATIVES OF PURINA 2, 6-SUBSTITUTES AND ITS USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS
CO2017005588A2 (en) 2-amino-5,5-difluoro-6- (fluoromethyl) -6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
UY34955A (en) 4-METHYL-2,3,5,9,9B-PENTAAZA-CICLOPENTA [A] NAFTALENOS
DOP2020000072A (en) SUBSTITUTE IMIDAZOPYRIDINE AMIDES AND THEIR USE
UY35551A (en) HETEROARILE DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
CO2019001181A2 (en) Heteroarylcarboxamide compounds as ripk2 inhibitors
PE20170088A1 (en) SPECIFIC ANTIBODIES OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR AND USES OF THEM
CL2017000827A1 (en) Aldosterone synthase inhibitors
CO2017000443A2 (en) 3h, 4h, 6h, 7h-pyran [3,4-d] imidazol-4-one derivatives active as aldosterone synthase inhibitors
BR112018004347A2 (en) pyrazolo [1,5-a] pyrimidine-3-carboxyamide cyclic ether derivatives
MX2019011265A (en) Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators.